Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.6258
+0.0169 (2.78%)
At close: Nov 26, 2025, 4:00 PM EST
0.6070
-0.0188 (-3.00%)
After-hours: Nov 26, 2025, 6:42 PM EST
Cue Biopharma Revenue
Cue Biopharma had revenue of $2.15M in the quarter ending September 30, 2025, a decrease of -35.58%. This brings the company's revenue in the last twelve months to $7.10M, down -25.51% year-over-year. In the year 2024, Cue Biopharma had annual revenue of $9.29M with 69.16% growth.
Revenue (ttm)
$7.10M
Revenue Growth
-25.51%
P/S Ratio
7.61
Revenue / Employee
$173,171
Employees
41
Market Cap
49.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CUE News
- 15 days ago - Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 21 days ago - Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 3 months ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 3 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 5 months ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire